Consumer healthcare group Futura Medical plc (AIM: FUM) disclosed on Monday that it has terminated its US commercial agreement with Haleon plc (LSE: HLN) (NYSE: HLN) and appointed Market Performance Group as its new US distribution partner for Eroxon, a topical gel treatment for ED, with the new distribution agreement taking effect on 1 September 2026.

Under the termination agreement, Futura will receive a USD1.9m early termination fee, while waiving its US patent milestone payment in exchange for the return of US commercial rights and ownership of Eroxon marketing assets developed by Haleon. Existing product inventory and marketing materials will transfer to Futura to support a seamless transition, with a Transitional Services Agreement in place until Market Performance Group assumes commercial control.

Under the new distribution model, Market Performance Group will manage US distribution and promotion of Eroxon, while Futura will retain responsibility for manufacturing and control of discretionary advertising and promotional spending. Futura said the arrangement provides greater commercial control and higher returns per unit sold than the previous out-licensing model.

The company said the return of US rights allows it to pursue the market on more favourable commercial terms and supports its strategy of taking a more active role in commercialising its products. Futura added that the termination payment, together with its existing cash resources, is expected to provide working capital into October 2026 while it continues to evaluate funding and strategic initiatives to extend its cash runway.